Literature DB >> 10782854

Bone mineral status in juvenile rheumatoid arthritis.

C E Rabinovich1.   

Abstract

Osteoporosis can be thought of as a disease of childhood with manifestations in the adult years. One strategy in prevention of osteoporosis is to maximize peak bone mass with interventions focused during the childhood and adolescent years, taking advantage of this unique window of opportunity to maximize bone mass accrual, maximize peak bone mass, and theoretically decrease fracture risk for life. Factors important in the development of peak bone mass in children are reviewed. Studies examining bone metabolism and bone density in children with juvenile rheumatoid arthritis (JRA) are summarized. There is much work to be done before the best treatments for the osteoporosis of JRA are defined. Optimizing calcium intake and physical activity, along with corticosteroid avoidance and control of disease activity, is sound management for children with JRA.

Entities:  

Mesh:

Year:  2000        PMID: 10782854

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  8 in total

Review 1.  Osteoporosis.

Authors:  R Cimaz; M Biggioggero
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

2.  Management of juvenile idiopathic arthritis.

Authors:  Sujata Sawhney
Journal:  Indian J Pediatr       Date:  2002-10       Impact factor: 1.967

3.  Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis.

Authors:  Reyhan Celiker; Serpil Bal; Aysin Bakkaloğlu; Eda Ozaydin; Turgay Coskun; Alp Cetin; Fitnat Dinçer
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

Review 4.  Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.

Authors:  Emily von Scheven; Kathleen Jo Corbin; Stefano Stagi; Stagi Stefano; Rolando Cimaz
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

5.  Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis.

Authors:  Pradip Kumar Sarma; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

6.  Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study.

Authors:  Gunhild Lien; Thor Ueland; Kristin Godang; Anne M Selvaag; Oystein T Førre; Berit Flatø
Journal:  Pediatr Rheumatol Online J       Date:  2010-12-06       Impact factor: 3.054

7.  Secondary osteoporosis in patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova
Journal:  J Osteoporos       Date:  2011-02-20

8.  Safety and feasibility of a home-based six week resistance training program in juvenile idiopathic arthritis.

Authors:  Cameron Van Oort; Susan M Tupper; Alan M Rosenberg; Jonathan P Farthing; Adam D Baxter-Jones
Journal:  Pediatr Rheumatol Online J       Date:  2013-12-20       Impact factor: 3.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.